About Anelixis Therapeutics
Anelixis Therapeutics is a company based in Cambridge (United States) founded in 2013 was acquired by Eledon in September 2020.. Anelixis Therapeutics has raised $12.86 million across 5 funding rounds from investors including Eledon and BVF Partners. Anelixis Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Anelixis Therapeutics
Anelixis Therapeutics has successfully raised a total of $12.86M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $6.0M
-
First Round
First Round
(20 Jun 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series B - Anelixis Therapeutics | Valuation |
investors |
|
| Nov, 2019 | Amount | Series B - Anelixis Therapeutics | Valuation | BVF Partners |
|
| May, 2019 | Amount | Debt – Conventional - Anelixis Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Anelixis Therapeutics
Anelixis Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eledon and BVF Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Anelixis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Anelixis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Anelixis Therapeutics Comparisons
Competitors of Anelixis Therapeutics
Anelixis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Anelixis Therapeutics
Frequently Asked Questions about Anelixis Therapeutics
When was Anelixis Therapeutics founded?
Anelixis Therapeutics was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Where is Anelixis Therapeutics located?
Anelixis Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Anelixis Therapeutics a funded company?
Anelixis Therapeutics is a funded company, having raised a total of $12.86M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1M, raised on Jun 20, 2017.
What does Anelixis Therapeutics do?
Anelixis Therapeutics, a subsidiary of ALS Therapy Development Institute (ALS TDI), is focussed on developing drugs for Amyotrophic lateral sclerosis (ALS). It currently has 2 clinical programs targeting the CD40, Tumor Necrosis Factor (TNF) and superoxide dismutase (SOD1) which play a role in the pathogenesis of ALS. In addition to the clinical assets, it has issued patents for the method of treatment of neurodegenerative diseases by targeting CD40 and the targeting of CD8 T-Lymphocytes to treat neurodegenerative diseases.
Who are the top competitors of Anelixis Therapeutics?
Anelixis Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Who are Anelixis Therapeutics's investors?
Anelixis Therapeutics has 2 investors. Key investors include Eledon, and BVF Partners.